Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 21:12:38·⟳ 抓取 21:13:34 +56s·⚡ 决策 08-21 21:23:51 +10m17s·66.9 天前
Scholar Rock移除Catalent Indiana作为apitegromab BLA商业灌装设施，FDA仍按9月30日PDUFA审评
本次Investing.com正文核心事实与Scholar Rock在2026-08-07已发布的公司公告相同，没有新增审批结论、PDUFA变更或商业化量级。
📄 原文Investing.com↗ 原文
Scholar Rock removes Catalent facility from SMA drug application
S&P 500 may pull back before midterms, but Citi says buy the dip CAMBRIDGE, Mass. - Scholar Rock (NASDAQ:SRRK) has remo…
不做 Scholar Rock（SRRK.US）
同一具体Catalent设施移除和第二灌装设施继续审评事项已在2026-08-07由公司公告披露，8月21日Investing.com稿无新增PDUFA、审批结论或量级信息，预期差不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司已披露Catalent Indiana OAI、移除该设施、FDA转由第二灌装设施继续审评且PDUFA维持2026-09-30。
- 行业媒体已在本次Investing.com稿件前转述同一Catalent设施移除和第二设施审评事实。
- Investing.com稿件为同一已披露事项的再传播，未提供新的FDA决定、时间表变化或增量金额。
关键理由
- 本次Investing.com正文核心事实与Scholar Rock在2026-08-07已发布的公司公告相同，没有新增审批结论、PDUFA变更或商业化量级。
- 利空点是Catalent设施OAI和欧洲MAA撤回，但替代设施审评与美国PDUFA日期维持不变，属于已披露监管制造事项的转述。
主要风险
- 若FDA最终要求额外CMC补件或推迟PDUFA，才会形成新的实质利空；本条没有新增该事实。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-07 · 影响 invalidates
公司早已确认同一事项且PDUFA未变，削弱把该稿作为新利好交易的理由。
检索:Scholar Rock apitegromab Catalent Indiana OAI second fill-finish PDUFA September 30 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-07 · 影响 weakens
虽然Catalent OAI是负面CMC事实，但第二设施审评继续且时间表未变，且该事实已传播两周，不支持新开空。
检索:Scholar Rock apitegromab Catalent Indiana OAI FDA review second fill-finish facility 原文 ↗
先例如何影响了这次决策
对本次决策的影响:重复旧闻直接降低新鲜度和预期差，最终不做。
方向:未使用先例定方向，因为本次研究在传播链核验后已判定为同一旧催化的重复传播。
涨幅量级:不适用，未进入可交易催化幅度校准。
形态:不适用。
原文全文
展开原文 · 1,906 字
S&P 500 may pull back before midterms, but Citi says buy the dip
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ:SRRK) has removed Catalent Indiana LLC as a commercial fill-finish facility from its apitegromab Biologics License Application for spinal muscular atrophy treatment in the U.S., the company said in a press release statement Wednesday.
The Food and Drug Administration is reviewing the BLA with Scholar Rock’s alternate fill-finish facility, and the company expects a decision by the September 30, 2026 Prescription Drug User Fee Act date. The company said it has commercial vials available from the alternate facility upon FDA approval.
Scholar Rock withdrew its apitegromab Marketing Authorisation Application with the European Medicines Agency’s Committee for Medicinal Products for Human Use on Thursday. The withdrawal followed the FDA’s August 7, 2026 classification of Catalent Indiana’s April 2026 inspection as Official Action Indicated. The company plans to resubmit the application with the alternate fill-finish facility.
The company also said Japan’s Pharmaceuticals and Medical Devices Agency agreed that no additional clinical studies are required for apitegromab regulatory submission. Scholar Rock expects to submit a Japanese New Drug Application for apitegromab by year-end 2026.
The alternate fill-finish facility is U.S.-based and produces commercial products, with recent FDA and EMA inspections, according to the company.
Apitegromab is an investigational monoclonal antibody that inhibits myostatin activation in skeletal muscle. The FDA has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment. The EMA granted Priority Medicines and Orphan Medicinal Product designations. The drug has not been approved by any regulatory agency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ:SRRK) has removed Catalent Indiana LLC as a commercial fill-finish facility from its apitegromab Biologics License Application for spinal muscular atrophy treatment in the U.S., the company said in a press release statement Wednesday.
The Food and Drug Administration is reviewing the BLA with Scholar Rock’s alternate fill-finish facility, and the company expects a decision by the September 30, 2026 Prescription Drug User Fee Act date. The company said it has commercial vials available from the alternate facility upon FDA approval.
Scholar Rock withdrew its apitegromab Marketing Authorisation Application with the European Medicines Agency’s Committee for Medicinal Products for Human Use on Thursday. The withdrawal followed the FDA’s August 7, 2026 classification of Catalent Indiana’s April 2026 inspection as Official Action Indicated. The company plans to resubmit the application with the alternate fill-finish facility.
The company also said Japan’s Pharmaceuticals and Medical Devices Agency agreed that no additional clinical studies are required for apitegromab regulatory submission. Scholar Rock expects to submit a Japanese New Drug Application for apitegromab by year-end 2026.
The alternate fill-finish facility is U.S.-based and produces commercial products, with recent FDA and EMA inspections, according to the company.
Apitegromab is an investigational monoclonal antibody that inhibits myostatin activation in skeletal muscle. The FDA has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment. The EMA granted Priority Medicines and Orphan Medicinal Product designations. The drug has not been approved by any regulatory agency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。